At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Hyman Muss, MD, of the University of North Carolina, Chapel Hill, NC, provides an update on the CALGB/CTSU/Alliance 49907 trial, which compared capecitabine with standard chemotherapy in patients with breast cancer who were at least 65 years old.
CALGB 49907 trial: Standard chemotherapy versus capecitabine for older women with breast cancer
21st August 2015
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.Join Now